Organogenesis Holdings Inc.
ORGONASDAQHealthcare● Active
$2.38
$-0.04(-1.65%)
Market Cap$306245424
P/E Ratio—
52W High$7.077
52W Low$2.04
Organogenesis Holdings Inc. (ORGO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ORGO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.37
Est. -$0.29 · -27.6%
Revenue
$0.04B
Est. $0.04B · -16.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
ORGO reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.03
Rev. $1.54B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.03
Rev. Est.$1.54B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.35 | — | — | — | $0.05B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.29 | -$0.37 | -27.6% | $0.04B | $0.04B | -16.2% |
| ▲ Q1 FY2026 | Feb 26, 2026 | $0.21 | $0.31 | +44.2% | $0.23B | $0.17B | +30.4% |
| ▼ Q4 FY2025 | Nov 6, 2025 | $0.21 | $0.18 | -14.3% | $0.15B | $0.17B | -12.6% |
| ▼ Q3 FY2025 | Aug 7, 2025 | $0.07 | -$0.09 | -228.6% | $0.10B | $0.13B | -24.7% |
| ▼ Q2 FY2025 | May 8, 2025 | $0.04 | -$0.13 | -425.0% | $0.09B | $0.09B | -4.5% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.03 | $0.04 | +233.3% | $0.13B | $0.11B | +15.6% |
| ▲ Q4 FY2024 | Nov 12, 2024 | $0.01 | $0.09 | +700.0% | $0.12B | $0.11B | +7.7% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.35
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.37
EPS Est.
-$0.29
EPS Surpr.
-27.6%
Revenue
$0.04B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
$0.31
EPS Est.
$0.21
EPS Surpr.
+44.2%
Revenue
$0.23B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
$0.18
EPS Est.
$0.21
EPS Surpr.
-14.3%
Revenue
$0.15B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.09
EPS Est.
$0.07
EPS Surpr.
-228.6%
Revenue
$0.10B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.13
EPS Est.
$0.04
EPS Surpr.
-425.0%
Revenue
$0.09B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
$0.04
EPS Est.
-$0.03
EPS Surpr.
+233.3%
Revenue
$0.13B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
$0.09
EPS Est.
$0.01
EPS Surpr.
+700.0%
Revenue
$0.12B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.10 | $0.10 | $0.10 | 1 |
| Q3 FY2028 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q2 FY2028 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q1 FY2028 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q4 FY2027 | $0.06 | $0.06 | $0.06 | 1 |
| Q3 FY2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -27.6% | $2.56 | $2.53 | -1.17% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +44.2% | $4.11 | $3.70 | -9.98% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -14.3% | $3.97 | $3.89 | -2.02% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -228.6% | $4.50 | $4.52 | +0.44% |
| ▼ Q2 FY2025 | May 8, 2025 | -425.0% | $5.18 | $5.34 | +3.09% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +233.3% | $3.25 | $3.07 | -5.54% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +700.0% | $3.50 | $3.45 | -1.43% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -550.0% | $2.50 | $2.62 | +4.80% |
Q2 FY2026-1.17%
Report Date
May 7, 2026
EPS Beat/Miss
-27.6%
Price Before
$2.56
Price After
$2.53
Q1 FY2026-9.98%
Report Date
Feb 26, 2026
EPS Beat/Miss
+44.2%
Price Before
$4.11
Price After
$3.70
Q4 FY2025-2.02%
Report Date
Nov 6, 2025
EPS Beat/Miss
-14.3%
Price Before
$3.97
Price After
$3.89
Q3 FY2025+0.44%
Report Date
Aug 7, 2025
EPS Beat/Miss
-228.6%
Price Before
$4.50
Price After
$4.52
Q2 FY2025+3.09%
Report Date
May 8, 2025
EPS Beat/Miss
-425.0%
Price Before
$5.18
Price After
$5.34
Q1 FY2025-5.54%
Report Date
Feb 27, 2025
EPS Beat/Miss
+233.3%
Price Before
$3.25
Price After
$3.07
Q4 FY2024-1.43%
Report Date
Nov 12, 2024
EPS Beat/Miss
+700.0%
Price Before
$3.50
Price After
$3.45
Q3 FY2024+4.80%
Report Date
Aug 8, 2024
EPS Beat/Miss
-550.0%
Price Before
$2.50
Price After
$2.62
Avg Beat Reaction-5.65%
Avg Miss Reaction+1.03%
Beat Rate3 / 8 quarters
Largest Move-9.98% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ORGO ends December
Organogenesis Holdings Inc. (ORGO) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.37 — missing the analyst consensus of $-0.29 by -27.6%. The next ORGO earnings date is expected around September 1, 2026.
Each quarter, investors track ORGO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ORGO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ORGO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ORGO earnings · 5 questionsOrganogenesis Holdings Inc.'s next earnings report is expected around September 1, 2026. ORGO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ORGO historically reports after market close (AMC).
ORGO earnings datewhen is ORGO earningsORGO next earnings datewhen does ORGO report earningsORGO earnings calendar
▸ Source: FMP · Organogenesis Holdings Inc. SEC filings · US GAAP · Organogenesis Holdings Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026